Abstract:Receptor-related orphan receptor γ (RORγ) has emerged as an attractive therapeutic target for the treatment of cancer and inflammatory diseases. Herein, we report our effort on the discovery, optimization, and evaluation of benzothiazole and benzimidazole derivatives as novel inverse agonists of RORγ. The representative compound 27h (designated as XY123) potently inhibited the RORγ transcription activity with a half-maximal inhibitory concentration (IC50) value of 64 nM and showed excellent selectivity against other nuclear receptors. 27h also potently suppressed cell proliferation, colony formation, and the expression of androgen receptor (AR)-regulated genes in AR-positive prostate cancer cell lines. In addition, 27h demonstrated good metabolic stability and a pharmacokinetic property with reasonable oral bioavailability (32.41%) and moderate half-life (t1/2 = 4.98 h). Significantly, oral administration of compound 27h achieved complete and long-lasting tumor regression in the 22Rv1 xenograft tumor model in mice. Compound 27h may serve as a new valuable lead compound for further development of drugs for the treatment of prostate cancer.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00763?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00763</a>.Virtual screening results from the molecular docking; compounds identified as hits against RORγ from virtual screening; overlaid complex structures of compound XY101 and compound 27h; overlaid structures of compounds 27g and 27h; western blot analysis of the AR and AR variants levels in 22Rv1 cells treated with compound 27h; metabolic stability of 25c, 25p, 27g, and 27h in human and rat liver microsomes; 1H and 13C NMR spectra of the synthesized compounds; and HPLC traces of representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_001.pdf">PDF</a>)Molecular formula strings for compounds with associated biological data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_002.csv">CSV</a>)Database files (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00763/suppl_file/jm1c00763_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Discovery of Biaryl Amide Derivatives As Potent, Selective, and Orally Bioavailable RORγt Agonists for Cancer Immunotherapy.

Discovery of Aryl-Substituted Indole and Indoline Derivatives As RORγt Agonists

Discovery of tert-amine-based RORγt agonists.

Discovery of Novel N-sulfonamide-tetrahydroisoquinolines As Potent Retinoic Acid Receptor-Related Orphan Receptor Γt Agonists

Discovery of <i>tert</i>-amine-based RORt agonists

Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer

Retinoic Acid Receptor-Related Orphan Receptor Γt (rorγt) Agonists As Potential Small Molecule Therapeutics for Cancer Immunotherapy.

Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists

Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) Pyridin-2-yl) Acetamide (b12) As a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor Γt Inverse Agonist.

Optimization of carbazole carboxamide RORγt agonists: Challenges in improving the metabolic stability and maintaining the agonistic activity

Discovery of 2H-Chromone-4-one Based Sulfonamide Derivatives As Potent Retinoic Acid Receptor-Related Orphan Receptor Γt Inverse Agonists.

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORγt agonists.

Discovery of Chromane-6-Sulfonamide Derivative As a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor Γt Inverse Agonist.

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORt agonists

Discovery of N -(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent RORγt inverse agonists

Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist

RORγt Agonist Enhances Anti-Pd-1 Therapy by Promoting Monocyte-Derived Dendritic Cells Through CXCL10 in Cancers.

Discovery of Novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides As Potent RORγt Inhibitors

Discovery and Structural Optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1h)-ones As RORc Inverse Agonists

Discovery of 3-(2-aminobenzo[d]thiazol-5-yl) Benzamide Derivatives As Potent Anticancer Agents Via ROR1 Inhibition

Discovery of N-indanyl Benzamides As Potent RORγt Inverse Agonists